Chemical stability and fate of the cytostatic drug ifosfamide and its N- dechloroethylated metabolites in acidic aqueous solutions

Journal of Medicinal Chemistry

Volumn 42, Issue 14, 1999, Pages 2542-2560

  Gilard, Véronique ^a   Martino, Robert ^a   Malet Martino, Myriam ^a   Niemeyer, Ulf ^b   Pohl, Jörg ^b  

^a Université Paul Sabatier   (France)

^b ASTA MEDICA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; IFOSFAMIDE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOSTASIS; DRUG DEGRADATION; DRUG STABILITY; LEUKEMIA; MOUSE; NONHUMAN;

AMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG STABILITY; FEMALE; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; IFOSFAMIDE; KINETICS; LETHAL DOSE 50; LEUKEMIA P388; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; NEOPLASM TRANSPLANTATION; PHOSPHORAMIDE MUSTARDS; PHOSPHORIC ACIDS; PHOSPHORUS ISOTOPES; RATS; TUMOR CELLS, CULTURED; WATER;

EID: 0033566213     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980587g     Document Type: Article

References (49)

1. Connors, T. A.; Cox, P. J.; Farmer, P. B.; Foster, A. B.; Jarman, M. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem. Pharmacol. 1974, 23, 115-129.
2. Sladek, N. E. Metabolism of oxazaphosphorines. Pharmacol. Ther. 1988, 37, 301-355.
3. Lind, M. J.; Ardiet, C. Pharmacokinetics of alkylating agents. Cancer Surveys 1993, 17, 157-188.
4. Sladek, N. E. Metabolism and pharmacokinetics behavior of cyclophosphamide and related oxazaphosphorines. In Anticancer Drugs: Reactive metabolism and drug interactions; Powis, G., Ed.; Pergamon Press: Oxford, 1994; pp 79-156.
5. Kaijser, G. P.; Beijnen, J. H.; Bult, A.; Underberg, W. J. M. Ifosfamide metabolism and pharmacokinetics. Anticancer Res. 1994, 14, 517-532.
6. Wagner, T. Ifosfamide clinical pharmacokinetics. Clin. Pharmacokinet. 1994, 26, 439-456.
7. Norpoth, K. Studies on the metabolism of isophosphamide in man. Cancer Treat. Rep. 1978, 60, 437-443.
8. 31P nuclear magnetic resonance spectroscopy. J. Pharmacol. Exp. Ther. 1992, 260, 1133-1144.
9. Gilard, V.; Malet-Martino, M. C.; de Forni, M.; Niemeyer, U.; Ader, J. C.; Martino, R: Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy. Cancer Chemother. Pharmacol. 1993, 31, 387-394.
10. Wang, J. J. H.; Chan, K. K. Identification of new metabolites of ifosfamide in rat urine using ion cluster technique. J. Mass Spectrom. 1995, 30, 675-683.
11. Goren, M. P.; Wright, R. K.; Pratt, C. B.; Pell, F. E. Dechloroethylation of ifosfamide and neurotoxicity. Lancet II 1986, 1219.
12. Pohl, J.; Stekar, J.; Hilgard, P. Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. Arzneim. Forsch. 1989, 39, 704-705.
13. 13C-chloroacetaldehyde, a metabolite of ifosfamide and cyclophosphamide, in the isolated perfused rabbit heart model. Initial observations on its cardiotoxicity and cardiac metabolism. Cell. Mol. Biol. 1997, 43, 773-782.
14. Kurowski, V.; Wagner, T. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, Chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother. Pharmacol. 1993, 33, 36-42.
15. Kaijser, G. P.; Beijnen, J. H.; Jeunink, E. L.; Bult, A.; Keizer, H. J.; de Kraker, J.; Underberg, W. J. M. Determination of chloroacetaldehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma. J. Chromatogr. 1993, 614, 253-259.
16. Kaijser, G. P.; Korst, A.; Beijnen, J. H.; Bult, A.; Underberg, W. J. M. The analysis of ifosfamide and its metabolites. Anticancer Res. 1993, 13, 1311-1324.
17. Momerency, G.; Van Cauwenberghe, K.; de Bruijn, E. A.; Van Oosterom, A. T.; Highley, M. S.; Harper, P. G. Determination of iphosphamide and seven metabolites in blood plasma, as stable trifluoroacetyl derivatives, by electron capture chemical ionization GC-MS. J. High Resolut. Chromatogr. 1994, 17, 655-661.
18. Kaijser, G. P.; Aalbers, T.; Beijnen, J. H.; Bult, A.; Underberg, W. J. M. Chemical stability of cyclophosphamide, trofosfamide, and 2- and 3-dechloroethylifosfamide in aqueous solutions. J. Oncol. Pharm. Pract. 1996, 2, 15-21.
19. Zon, G.; Ludeman, S. M.; Egan, W. High-resolution nuclear magnetic resonance investigations of the chemical stability of cyclophosphamide and related phosphoramidic compounds. J. Am. Chem. Soc. 1977, 99, 5785-5795.
20. Trissel, L. A.; Kleinman, L. M.; Cradock, J. C.; Davignon, J. P. Investigational drug information. Drug Intell. Clin. Pharm. 1979, 13, 340-343.
21. Radford, J. A.; Margison, J. M.; Swindell, R.; Lind, M. J.; Wilkinson, P. M.; Thatcher, N. The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. Cancer Chemother. Pharmacol. 1990, 26, 144-146.
22. Kaijser, G. P.; Beijnen, J. H.; Bult, A.; Hogeboom, M. H.; Underberg, W. J. M. A systematic study on the chemical stability of ifosfamide. J. Pharm. Biomed. Anal. 1991, 9, 1061-1067.
23. Muñoz, M.; Girona, V.; Pujol, M.; Durán, S.; Vicente, P.; Solé, L. A. Stability of ifosfamide in 0.9% sodium chloride solution or water for injection in a portable i.v. pump cassette. Am. J. Hosp. Pharm. 1992, 49, 1137-1139.
24. Muñoz, M.; Bonjoch, J.; Prat, J.; Pujol, M.; Girona, V.; de Bolos, J. Degradation kinetics of ifosfamide in aqueous solution, Int. J. Pharm. 1996, 139, 249-253.
25. Leone, L.; Comandone, A.; Oliva, C.; Bussi, P.; Goffredo, F.; Bretti, S.; Bumma, C. Stability of ifosfamide in solutions for multiday infusion by external pump. Anti-Cancer Drugs 1995, 6, 604-607.
26. Highley, M. S.; Momerency, G.; Van Cauwenberghe, K.; Van Oosterom, A. T.; de Bruijn, E. A.; Maes, R. A. A.; Blake, P.; Mansi, J.; Harper, P. G. Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans. Drug Metab. Dispos. 1995, 23, 433-437.
27. Hill, S.; Aexiou, J.; Kavanagh, P. E.; Livingstone, P. C.; Shalliker, R. A.; Soscic, J. Separation of ifosfamide and its degradation products using micellar electrokinetic chromatography. Anal. Commun. 1996, 33, 235-237.
28. Gilard, V.; Martino, R.; Malet-Martino, M. C.; Kutscher, B.; Müller, A.; Niemeyer, U.; Pohl, J.; Polymeropoulos, E. E. Chemical and biological evaluation of hydrolysis products of cyclophosphamide. J. Med. Chem. 1994, 37, 3986-3993.
29. Dermer, O. C.; Ham, G. E. Ethylenimine and other aziridines; Academic Press: New York, 1969.
30. 13C NMR spectra.
31. Yonezawa, T.; Morishima, I.; Fukuta, K. Solvent effects in NMR spectroscopy. II. A repulsive interaction between the benzene solvent molecule and the nitrogen lone-pair, and the effects induced by the addition of protic substances. Bull. Chem. Soc. Jpn. 1968, 41, 2297-2305.
32. Gamcsik, M.; Ludeman, S. M.; Shulman-Roskes, E. M.; McLennan, I. J.; Colvin, M. E.; Colvin, O. M. Protonation of phosphoramide mustard and other phosphoramides. J. Med. Chem. 1993, 36, 3636-3645.
33. Albert, A.; Serjeant, E. P. Ionization constants of acids and bases; John Wiley and Sons: New York, 1962.
34. Öney, I.; Caplow, M. Phosphoramidate Solvolysis. J. Am. Chem. Soc. 1967, 89, 6972-6980.
35. Millis, K. K.; Colvin, M. E.; Shulman-Roskes, E. M.; Ludeman, S. M.; Colvin, O. M.; Gamcsik, M. P. Comparison of the protonation of isophosphoramide mustard and phosphoramide mustard. J. Med. Chem. 1995, 38, 2166-2175.
36. Koizumi, T.; Haake, P. Acid-catalyzed and alkaline hydrolyses of phosphinamides. The lability of phosphorus - nitrogen bonds in acid and the mechanisms of reaction. J. Am. Chem. Soc. 1973, 95, 8073-8079.
37. Rahil, J.; Haake, P. Reactivity and mechanism of hydrolysis of phosphonamides. J. Am. Chem. Soc. 1981, 103, 1723-1734.
38. Modro, T. A.; Graham, D. H. Phosphoric Amides. 3. Acidic cleavage of the phosphorus - nitrogen bond in acyclic and cyclic phosphoramidates. J. Org. Chem. 1981, 46, 1923-1925.
39. 1 character. Acid-catalyzed hydrolysis of phosphinanilides. J. Am. Chem. Soc. 1973, 95, 8066-8072.
40. Guard, V.; Martino, R.; Malet-Martino, M.; Niemeyer, U. Stability of commercial formulations and aqueous solutions of ifosfamide (a reply). Drug Metab. Dispos. 1997, 25, 927-931.
41. Le Roux, C.; Modro, A. M.; Modro, T. A. Decomposition of N-phosphorylated nitrogen mustards: a mechanistic investigation. J. Org. Chem. 1995, 60, 3832-3839.
42. Wan, H.; Modro, T. A. Chemistry of N-phosphorylated nitrogen mustards: the effect of a second nitrogen substituent at phosphorus on the stability of the system. Phosphorus, Sulfur Silicon 1996, 108, 155-168.
43. 31P NMR spectroscopy. NMR spectroscopy of the non metallic elements; John Wiley and Sons: Chichester, England, 1997; pp 700-1019.
44. Joqueviel, C.; Martino, R.; Guard, V.; Malet-Martino, M.; Canal, P.; Niemeyer, U. Urinary excretion of cyclophosphamide in humans, determined by phosphorus-31 nuclear magnetic resonance spectroscopy. Drug Metab. Dispos. 1998, 26, 418-428.
45. Sociedad Espanola Especialidades Farmaco-Therapeuticas SA. Preparation of ifosfamide. Spanish Pat. ES 526194, 1985; Chem. Abstr. 1987, 107, 7385r.
46. Joqueviel, C.; Guard, V.; Martino, R.; Malet-Martino, M.; Niemeyer, U. Urinary stability of carboxycyclophosphamide and carboxyifosfamide, two major metabolites of the anticancer drugs cyclophosphamide and ifosfamide. Cancer Chemother. Pharmacol. 1997, 40, 391-399.
47. 4 reaction: origin of the bistability in a CSTR. J. Phys. Chem. 1995, 99, 14365-14371.
48. 31P nuclear magnetic resonance titrations. Simultaneous evaluation of all pH-dependent resonance signals. Org. Magn. Reson. 1984, 22, 101-105.
49. Hamburger, A. W.; Salmon, S. E. Primary bioassay of human myeloma stem cells. J. Clin. Invest. 1977, 60, 846-854.